Recovery from Acute Experimental Autoimmune Encephalomyelitis (EAE) Characterized by Endothelial Cell Unresponsiveness to Cytokines and Pericyte Activation

  • Paula Dore-Duffy
  • Roumen Balabanov
  • Ruth Washington
Part of the Advances in Behavioral Biology book series (ABBI, volume 46)


Experimental allergic encephalomyelitis (EAE) is an antigen-driven T-cell-mediated autoimmune disease in animals that closely resembles the human disease multiple sclerosis (MS). In rats, EAE is characterized by an acute clinical phase followed by recovery (1). The mechanism by which animals recover from the paralytic disease is unknown. It is thought that cytokine-mediated regulation by T-suppressor cells plays an important role (2–4). Transforming growth factor beta-1 (TGFβ-1), is a naturally occurring immunoregulatory protein (5) which has emerged as a leading candidate in immunoregulation of EAE (6–14). The mechanisms by which TGFβ1 ameliorates the incidence and severity of EAE is not well understood, but a primary effect on macrophage and/or T-cell-mediated immune function or on the blood brain barrier (BBB) has been suggested (6,9,13–18) In a previous study, we have reported that TGF131 inhibits interferon gamma (IFNγ)-mediated activation of rat central nervous system (CNS) microvessel endothelial cells (EC) and that TGFβ1 pretreated EC are unresponsive to subsequent stimulation (19). In the present study, we examine in culture, CNS microvessels from Lewis rats through induction, clinically apparent disease, and in the recovery phase of EAE for the expression of EC activation antigens and for sensitivity to further activation with IFNγ. Expression of activation antigens is sequential and precedes appearance of clinical symptoms. Results further indicate that recovery from EAE is, in part, characterized by EC unresponsiveness to IFNγ, and vascular pericyte reactivity.


Experimental Allergic Encephalomyelitis Myelin Basic Protein Post Inoculation Experimental Allergic Encephalomyelitis Microvessel Endothelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paterson PY, Swanborg RH. (1988): Demyelinating diseases of the central and peripheral nervous systems. In: M. Samster (ed), Immunological Diseases, 4th ed., Little Brown, pp. 1877.Google Scholar
  2. 2.
    Bernard CCA. (1977): Suppresser cells prevent experimental autoimmune encephalomyelitis in mice. Clin. Exp. Immunol. 29: 100–111.PubMedGoogle Scholar
  3. 3.
    Karpus WJ, Swanborg RH. (1989): CD4+ suppressor cells differentially affect the production of IFNγ by effector cells of experimental autoimmune encephalomyelitis. J. Immunol. 143: 3492–3501.PubMedGoogle Scholar
  4. 4.
    Zamvill SS, Steinman L. (1990): The T lymphocyte in experimental allergic encephalomyelitis. Ann. Rev. Immunol. 8: 579–632.Google Scholar
  5. 5.
    Massaque J. (1990): The transforming growth factor-(3 family. Ann. Rev. Cell Biol. 6: 597–620.CrossRefGoogle Scholar
  6. 6.
    Karpus WJ, Swanborg RH. (1991): CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor beta. J. Immunol. 146: 1163–1168.PubMedGoogle Scholar
  7. 7.
    Johns LD, Flanders KC, Ranges GE, Sriram S. (1991): Successful treatment of experimental allergic encephalomyelitis with transforming growth factor beta-1. J. Immunol. 147: 1792–1796.PubMedGoogle Scholar
  8. 8.
    Racke MK, Cannella B, Albert P, Spron M, Raine CS, McFarlin DE. (1992): Evidence of endogenous regulatory function of transforming growth factor-(31 in experimental allergic encephalomyelitis. Int. Immunol. 5: 615–620.Google Scholar
  9. 9.
    Stevens DB, Gould KE, Swanborg RH. (1994): Transforming growth factor-f31 inhibits tumor necrosis factor-a/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. 51: 77–83.Google Scholar
  10. 10.
    Mustafa M, Vingsbo C, Olsson T, Issazadeh J, Ljungdahl A, Holmdahl R. (1994): Protective influences on experimental autoimmune encephalomyelitis by MHC Class I and Class II alleles. J. Immunol. 153: 3337–3344.PubMedGoogle Scholar
  11. 11.
    Santambrogio L, Hochwald GM, Leu CH, Thorbecke GJ. (1993): Antagonistic effects of endogenous and exogenous TGF-beta and TNF on auto-immune diseases in mice. Immunopharma. & Immunotoxicol. 15: 461–78.CrossRefGoogle Scholar
  12. 12.
    Santambrogio L, Hochwald GM, Saxena B, Leu CH, Martz JE, Carlino JA, Ruddle NH, Palladino MA, Gold LI, Thorbecke GJ. (1993): Studies of the mechanisms by which transforming growth factor-beta (TGFß) protects against allergic encephalomyelitis. Antagonism between TGFß and tumor necrosis factor. J. Immunol. 151: 7307–7315.Google Scholar
  13. 13.
    Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. (1992): Suppressor T cells generated by oral toleration to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor 13 after antigen-specific triggering. Proc. Natl. Acad. Sci, 89: 421–425.Google Scholar
  14. 14.
    Fabry H, Topham DJ, Fee D, Herlein J, Carlino JA, Hart MN, Sriram S. (1995): TGF-ß2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J. Immunol. 155: 325–332.PubMedGoogle Scholar
  15. 15.
    Racke MK, Dhib-Jalbut S, Canella B, Albert PS, McFarlin DE. (1991): Evidence of endogenous regulatory function of transforming growth factor-131 in experimental allergic encephalomyelitis. Int. Immunol. 5: 615–620.Google Scholar
  16. 16.
    Miller A, Al-Sabbagh A, Santos LM, Das MP, Weiner HL. (1993): Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven by bystander suppression. J. Immunol. 125: 7307–7315.Google Scholar
  17. 17.
    Johns LD, Sriram S. (1993): Experimental allergic encephalomyelitis: Neutralizing antibody to TGFß1 enhances the clinical severity of the disease. J. Neuroimmun. 47: 1–7.CrossRefGoogle Scholar
  18. 18.
    Santos LM, Al-Sabbagh A, London A, Wiener HL. (1994): Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T-cells in Peyer’s patches of SJL Mice. Cell. Immunol. 157: 439–447.Google Scholar
  19. 19.
    Dore-Duffy, P, Balabanov R, Washington R, Swanborg R. (1994a): Transforming growth factor beta-1 inhibits cytokine-induced CNS endothelial cell activation. Molec. Chem. Neuropath. 22: 161–175.Google Scholar
  20. 20.
    Bowman PD, Betz AJ, Ard D, Wolinsky JS, Penney JB. Shiver RR, Goldstein GW. (1981): Primary culture of capillary endothelium from rat brain. In Vitro. 17: 353–362.Google Scholar
  21. 21.
    Joo F., Karnushina I. (1973): A procedure for the isolation of capillaries from rat brain. Cytobios. 8: 41–48.PubMedGoogle Scholar
  22. 22.
    Dore-Duffy P, Washington R, Balabanov R. (19946): Cytokine-mediated activation of cultured CNS microvessels: A system for examining antigenic modulation of CNS endothelial cell activation. Molec. Chem. Neuropath. 22: 161–175.Google Scholar
  23. 23.
    Herman I, D’Amore PA. (1985): Microvascular pericytes contain muscle and nonmuscle actins. J. Cell. Biol. 101: 43–52.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Paula Dore-Duffy
    • 1
  • Roumen Balabanov
    • 1
  • Ruth Washington
    • 1
  1. 1.Department of Neurology, Division of NeuroimmunologyWayne State University School of MedicineDetroitUSA

Personalised recommendations